myeloid metaplasia


Also found in: Dictionary, Thesaurus, Encyclopedia.

metaplasia

 [met″ah-pla´zhah]
the change in the type of adult cells in a tissue to a form abnormal for that tissue. adj., adj metaplas´tic.
agnogenic myeloid metaplasia the primary or idiopathic form of myeloid metaplasia, which is often accompanied by myelofibrosis; it is considered one of the myeloproliferative disorders. Called also aleukemic or nonleukemic myelosis.
myeloid metaplasia the occurrence of myeloid tissue in extramedullary sites; specifically, a syndrome characterized by splenomegaly, anemia, nucleated erythrocytes and immature granulocytes in the circulating blood, and extramedullary hematopoiesis in the liver and spleen. The primary form is called agnogenic myeloid metaplasia. The secondary or symptomatic form may be associated with various diseases, including carcinomatosis, tuberculosis, leukemia, and polycythemia vera.

my·e·loid met·a·pla·si·a

a syndrome characterized by anemia, enlargement of the spleen, nucleated red blood cells and immature granulocytes in the circulating blood, and conspicuous foci of extramedullary hemopoiesis in the spleen and liver; may develop in the course of polycythemia rubra vera; there is a high incidence of development of myeloid leukemia.

myeloid metaplasia

a disorder in which bone marrow tissue develops in abnormal sites. Characteristics of the condition are anemia, splenomegaly, immature blood cells in the circulation, and hematopoiesis in the liver and spleen. Myeloid metaplasia may be secondary to carcinoma, leukemia, polycythemia vera, or tuberculosis. The primary form is called agnogenic myeloid metaplasia, aleukemic myelosis.

chronic idiopathic myelofibrosis

A chronic progressive condition characterised by panmyelosis and variable marrow fibrosis, massive splenomegaly secondary to extramedullary haematopoiesis, and leukoerythroblastic anaemia with dysmorphic red blood cells, circulating normoblasts, immature white blood cells and atypical platelets.
 
Clinical findings
Patients are often > age 50, suffer from insidious weight loss, anaemia, and abdominal discomfort due to splenomegaly, often with hepatomegaly; 80% have nonspecific chromosome defects.
 
Diagnosis
Bone marrow biopsy.
 
Management
No specific therapy; packed RBCs for anaemia; androgens may reduce transfusion requirements, but are poorly tolerated in women; recombinant erythropoietin.
 
Prognosis
Survival ± 5 years, often progresses to acute leukaemia.

Terminology
No name used for this condition has proven consistently satisfactory to those who work in the field. Chronic idiopathic myelofibrosis is preferred by the World Health Organisation, while others prefer the term primary myelofibrosis. None of the terms fully take into account the functional defects—e.g., haemopoietic stem cell disturbance, extramedullary haemopoiesis and the pathological changes seen in the bone marrow (e.g., intense marrow fibrosis).

my·e·loid met·a·pla·si·a

(mī'ĕ-loyd met'ă-plā'zē-ă)
A syndrome characterized by anemia, enlargement of the spleen, nucleated red blood cells and immature granulocytes in the blood, and foci of extramedullary hemopoiesis in the spleen and liver; may develop in the course of polycythemia rubra vera; there is a high incidence of development of myeloid leukemia.

myeloid

1. pertaining to, derived from or resembling bone marrow.
2. pertaining to the spinal cord.
3. having the appearance of myelocytes, but not derived from bone marrow.

myeloid:erythroid (M:E) ratio
the ratio of myeloid to erythroid cells found in an examination of the bone marrow; provides an assessment of bone marrow activity.
myeloid leukemia
see myelocytic leukemia.
myeloid leukosis
myeloid metaplasia
hyperplasia of the bone marrow, with erythroid phthisis and compensatory splenomegaly and sometimes hepatomegaly. It is usually succeeded by bone marrow fibrosis and sclerosis. The initiating cause is usually not apparent.
myeloid tissue
red bone marrow.
References in periodicals archive ?
Coverage of the Myeloid Metaplasia pipeline on the basis of route of administration and molecule type.
Identify and understand important and diverse types of therapeutics under development for Myeloid Metaplasia.
Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia.
Prognostic relevance of cytogenetics determined by fluorescent in situ hybridization in patients having myelofibrosis with myeloid metaplasia.
Phase 2 trials have been initiated in Hodgkin's Lymphoma and in myelofibrosis with myeloid metaplasia.
Ten patients each with either agnogenic myeloid metaplasia, polycythemia vera, or primary thrombocytothemia will be given low dose oral interferon alpha daily for 6-12 months as a treatment to relieve the signs and symptoms associated with these disorders.

Full browser ?